Hybrid gelatin-ascorbyl phosphate scaffolds accelerate diabetic wound healing via ROS scavenging, angiogenesis and collagen remodeling
Copyright © 2024. Published by Elsevier B.V..
Skin wound healing, particularly diabetic wound healing, is challenging in clinical management. Impaired wound healing is associated with persistent oxidative stress, altered inflammatory responses, unsatisfactory angiogenesis and epithelialization. Magnesium ascorbyl phosphate (MAP), which is an ascorbic acid derivative and active ingredient in cosmetics, has been reported to scavenge reactive oxygen species (ROS), and is considered a potential therapeutic agent for diabetic wounds. Herein, we report a hybrid gelatin-MAP scaffolds that can reduces oxidative stress damage, enhances angiogenesis and collagen remodeling to accelerate diabetic wound repair. Preliminary insights based on network pharmacology indicate that MAP may accelerate wound repair through multiple biological pathways, including extracellular matrix remodeling and anti-apoptosis. In vitro studies showed that the hybrid hydrogel scaffold had suitable mechanical properties, excellent biocompatibility and bioactivity. Further animal experiments demonstrated that the hydrogel accelerated full-thickness wound repair in diabetic mice (repair rate MAP vs Control=91.791±3.306 % vs 62.962±6.758 %) through antioxidant, neuroangiogenesis, collagen remodeling, and up-regulated the expression of the related factors COL-1, CD31, VEGF, and CGRP. Overall, we developed a bioactive hybrid hydrogel encapsulating MAP that synergistically promotes diabetic wound repair through multiple biological effects. This potentially integrated therapeutic scaffold may enrich future surgical approaches for treating diabetic wounds.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:158 |
|---|---|
| Enthalten in: |
Biomaterials advances - 158(2024) vom: 01. März, Seite 213779 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Zhen [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.03.2024 Date Revised 04.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bioadv.2024.213779 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367683156 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367683156 | ||
| 003 | DE-627 | ||
| 005 | 20240304232339.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240127s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bioadv.2024.213779 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1316.xml |
| 035 | |a (DE-627)NLM367683156 | ||
| 035 | |a (NLM)38277902 | ||
| 035 | |a (PII)S2772-9508(24)00022-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Zhen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hybrid gelatin-ascorbyl phosphate scaffolds accelerate diabetic wound healing via ROS scavenging, angiogenesis and collagen remodeling |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2024 | ||
| 500 | |a Date Revised 04.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024. Published by Elsevier B.V. | ||
| 520 | |a Skin wound healing, particularly diabetic wound healing, is challenging in clinical management. Impaired wound healing is associated with persistent oxidative stress, altered inflammatory responses, unsatisfactory angiogenesis and epithelialization. Magnesium ascorbyl phosphate (MAP), which is an ascorbic acid derivative and active ingredient in cosmetics, has been reported to scavenge reactive oxygen species (ROS), and is considered a potential therapeutic agent for diabetic wounds. Herein, we report a hybrid gelatin-MAP scaffolds that can reduces oxidative stress damage, enhances angiogenesis and collagen remodeling to accelerate diabetic wound repair. Preliminary insights based on network pharmacology indicate that MAP may accelerate wound repair through multiple biological pathways, including extracellular matrix remodeling and anti-apoptosis. In vitro studies showed that the hybrid hydrogel scaffold had suitable mechanical properties, excellent biocompatibility and bioactivity. Further animal experiments demonstrated that the hydrogel accelerated full-thickness wound repair in diabetic mice (repair rate MAP vs Control=91.791±3.306 % vs 62.962±6.758 %) through antioxidant, neuroangiogenesis, collagen remodeling, and up-regulated the expression of the related factors COL-1, CD31, VEGF, and CGRP. Overall, we developed a bioactive hybrid hydrogel encapsulating MAP that synergistically promotes diabetic wound repair through multiple biological effects. This potentially integrated therapeutic scaffold may enrich future surgical approaches for treating diabetic wounds | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Angiogenesis | |
| 650 | 4 | |a Antioxidant | |
| 650 | 4 | |a Ascorbyl phosphate | |
| 650 | 4 | |a Diabetic wound | |
| 650 | 4 | |a Hybrid hydrogel | |
| 650 | 7 | |a Gelatin |2 NLM | |
| 650 | 7 | |a 9000-70-8 |2 NLM | |
| 650 | 7 | |a Reactive Oxygen Species |2 NLM | |
| 650 | 7 | |a ascorbate-2-phosphate |2 NLM | |
| 650 | 7 | |a 23313-12-4 |2 NLM | |
| 650 | 7 | |a Collagen |2 NLM | |
| 650 | 7 | |a 9007-34-5 |2 NLM | |
| 650 | 7 | |a Ascorbic Acid |2 NLM | |
| 650 | 7 | |a PQ6CK8PD0R |2 NLM | |
| 650 | 7 | |a Hydrogels |2 NLM | |
| 650 | 7 | |a Phosphates |2 NLM | |
| 700 | 1 | |a Huang, Chunlin |e verfasserin |4 aut | |
| 700 | 1 | |a Guan, Shiyao |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Liying |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Hanxiao |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Junqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Jun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomaterials advances |d 2022 |g 158(2024) vom: 01. März, Seite 213779 |w (DE-627)NLM33548042X |x 2772-9508 |7 nnns |
| 773 | 1 | 8 | |g volume:158 |g year:2024 |g day:01 |g month:03 |g pages:213779 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bioadv.2024.213779 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 158 |j 2024 |b 01 |c 03 |h 213779 | ||